Consulta: creatorFacets:"Pereira,I.V.A."
Registros recuperados: 1
Data/hora: 27/07/2024 08:20:47

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
Provedor de dados: 56
Autores: Stefano,J.T.; Pereira,I.V.A.; Torres,M.M.; Bida,P.M.; Coelho,A.M.M.; Xerfan,M.P.; Cogliati,B.; Barbeiro,D.F.; Mazo,D.F.C.; Kubrusly,M.S.; D'Albuquerque,L.A.C.; Souza,H.P.; Carrilho,F.J.; Oliveira,C.P.
Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) received vehicle and the sorafenib group (n=10) received 2.5 mg·kg-1·day-1 by gavage. A control group (n=4) received only standard diet and vehicle. Following treatment, animals were sacrificed and liver tissue was collected for histologic examination, mRNA isolation, and analysis of mitochondrial function. Genes related to fibrosis (MMP9, TIMP1, TIMP2), oxidative stress (HSP60, HSP90, GST), and...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: NASH; Fibrosis; Mitochondrial dysfunction; Sorafenib.
Ano: 2015
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000500408